Literature DB >> 17684148

Insulin-like growth factors and ovarian cancer risk: a nested case-control study in three cohorts.

Shelley S Tworoger1, I-Min Lee, Julie E Buring, Michael N Pollak, Susan E Hankinson.   

Abstract

Insulin-like growth factor (IGF)-related hormones and binding proteins (IGFBP) have been implicated in cancer risk. Specifically, two recent, small prospective studies reported a significant positive association between IGF-I and ovarian cancer risk among women diagnosed before age 55 years. Therefore, we examined whether plasma concentrations of IGF-I, IGFBP-3, and IGFBP-2 were associated with risk of epithelial ovarian cancer in a nested case-control study using data from three prospective cohorts: the Nurses' Health Study (NHS), NHSII, and the Women's Health Study (WHS). The present study had 222 cases (159 from NHS/NHSII and 63 from WHS) and 599 controls (matching ratio, 1:3 for NHS/NHSII and 1:2 for WHS). Women ranged in age from 34 to 73 years (mean, 56 years). The relative risk (RR) comparing the top versus bottom quartile of IGF-I was 0.56 (95% confidence interval, 0.32-0.97; P(trend) = 0.14). The risk did not differ by age at diagnosis (comparable RR for age <55 years at diagnosis, 0.70; RR for age >/=55 years at diagnosis, 0.52). We did not observe any association between IGFBP-3, IGFBP-2, and the ratio of IGF-I to either binding protein and ovarian cancer risk. Overall, our results do not support a positive association between IGF-related proteins and ovarian cancer risk. (Cancer Epidemiol Biomarkers Prev 2007;16(8):1691-5).

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17684148     DOI: 10.1158/1055-9965.EPI-07-0319

Source DB:  PubMed          Journal:  Cancer Epidemiol Biomarkers Prev        ISSN: 1055-9965            Impact factor:   4.254


  18 in total

1.  Genetic variation in insulin-like growth factor 2 may play a role in ovarian cancer risk.

Authors:  Celeste Leigh Pearce; Jennifer A Doherty; David J Van Den Berg; Kirsten Moysich; Chris Hsu; Kara L Cushing-Haugen; David V Conti; Susan J Ramus; Aleksandra Gentry-Maharaj; Usha Menon; Simon A Gayther; Paul D P Pharoah; Honglin Song; Susanne K Kjaer; Estrid Hogdall; Claus Hogdall; Alice S Whittemore; Valerie McGuire; Weiva Sieh; Jacek Gronwald; Krzysztof Medrek; Anna Jakubowska; Jan Lubinski; Georgia Chenevix-Trench; Jonathan Beesley; Penelope M Webb; Andrew Berchuck; Joellen M Schildkraut; Edwin S Iversen; Patricia G Moorman; Christopher K Edlund; Daniel O Stram; Malcolm C Pike; Roberta B Ness; Mary Anne Rossing; Anna H Wu
Journal:  Hum Mol Genet       Date:  2011-03-21       Impact factor: 6.150

2.  Plasma insulin-like growth factor-1 level and risk of incident hypertension in nondiabetic women.

Authors:  Luxia Zhang; Gary C Curhan; John P Forman
Journal:  J Hypertens       Date:  2011-02       Impact factor: 4.844

3.  Body size in early life and adult levels of insulin-like growth factor 1 and insulin-like growth factor binding protein 3.

Authors:  Elizabeth M Poole; Shelley S Tworoger; Susan E Hankinson; Eva S Schernhammer; Michael N Pollak; Heather J Baer
Journal:  Am J Epidemiol       Date:  2011-08-09       Impact factor: 4.897

4.  Association of circulating insulin-like growth factor 1 and insulin-like growth factor binding protein 3 with the risk of ovarian cancer: A systematic review and meta-analysis.

Authors:  Qiao Wang; C E Bian; Hongling Peng; Lei He; Xia Zhao
Journal:  Mol Clin Oncol       Date:  2015-02-25

5.  Clinical significance of serum insulin-like growth factor-1 (IGF-1) and insulinlike growth factor binding protein-3 (IGFBP-3) in patients with epithelial ovarian cancer.

Authors:  Faruk Tas; Senem Karabulut; Murat Serilmez; Rumeysa Ciftci; Derya Duranyildiz
Journal:  Tumour Biol       Date:  2013-11-20

Review 6.  Insulin-like growth factor: current concepts and new developments in cancer therapy.

Authors:  Erin R King; Kwong-Kwok Wong
Journal:  Recent Pat Anticancer Drug Discov       Date:  2012-01       Impact factor: 4.169

7.  Anti-tumor effects of adenovirus containing human growth hormone sequences in a mouse model of human ovarian cancer.

Authors:  Yonglian Zhu; José B Fariña; Syrus Meshack; Ana Santoveña; Shilpa Patel; Alexis Oliva; Matias Llabrés; Michael E Hodsdon; Carmen J Booth; Priscilla S Dannies
Journal:  Endocrine       Date:  2010-04-20       Impact factor: 3.633

8.  Pre-diagnosis insulin-like growth factor-I and risk of epithelial invasive ovarian cancer by histological subtypes: A collaborative re-analysis from the Ovarian Cancer Cohort Consortium.

Authors:  Jennifer Ose; Helena Schock; Elizabeth M Poole; Matti Lehtinen; Kala Visvanathan; Kathy Helzlsouer; Julie E Buring; I-Min Lee; Anne Tjønneland; Marie-Christine Boutron-Ruault; Antonia Trichopoulou; Amalia Mattiello; N Charlotte Onland-Moret; Elisabete Weiderpass; María-José Sánchez; Annika Idahl; Ruth C Travis; Sabina Rinaldi; Melissa A Merritt; Nicolas Wentzensen; Shelley S Tworoger; Rudolf Kaaks; Renée T Fortner
Journal:  Cancer Causes Control       Date:  2017-02-16       Impact factor: 2.506

9.  Common genetic variation in IGF1, IGFBP1 and IGFBP3 and ovarian cancer risk.

Authors:  Kathryn L Terry; Shelley S Tworoger; Margaret A Gates; Daniel W Cramer; Susan E Hankinson
Journal:  Carcinogenesis       Date:  2009-12       Impact factor: 4.944

10.  Targeting insulin and insulin-like growth factor pathways in epithelial ovarian cancer.

Authors:  Marie-Claude Beauchamp; Amber Yasmeen; Ariane Knafo; Walter H Gotlieb
Journal:  J Oncol       Date:  2010-01-05       Impact factor: 4.375

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.